One strategy to improve “immunotherapy” could include combining the GM.CD40L vaccine (to expand the number of tumor-reactive T cells) with anti-PD1 therapy to allow T cells to remain functional when they enter into the tumor microenvironment. This evidence concerns the gene CD40LG and neoplasm.